TriMas Corporation (NASDAQ:TRS) shares advanced 1.78% in last trading session and ended the day at $17.11. TRS Gross Margin is 25.80% and its has a return on assets of 2.60%. TriMas Corporation (NASDAQ:TRS) quarterly performance is -28.76%.
Headquartered in Bloomfield Hills, Michigan, TriMas Corporation (TRS) provides engineered and applied products for growing markets worldwide. TriMas is organized into four reportable segments: Packaging, Aerospace, Energy and Engineered Components. TriMas has approximately 4,000 employees at more than 50 facilities in 16 countries.
On 9 September TriMas Corporation (NASDAQ:TRS) –announced a broadly-focused Financial Improvement Plan expected to improve the Company’s profitability, cash flow conversion and operational efficiency, and deliver increased shareholder value.
iKang Healthcare Group, Inc. (NASDAQ:KANG) ended the last trading day at $14.77. Company weekly volatility is calculated as 6.14% and price to cash ratio as 15.81. iKang Healthcare Group, Inc. (NASDAQ:KANG) showed a weekly performance of -2.38%.
iKang Healthcare Group, Inc. is the largest provider in China’s fast growing private preventive healthcare services market, accounting for approximately 13.6% of market share in terms of revenue in calendar year 2014.
On 10 September, iKang Healthcare Group, Inc. (NASDAQ:KANG), announced that in response to the preliminary non-binding proposal dated August 31, 2015 (the “Proposal”) received by the Company’s board of directors (the “Board”) from Mr. Ligang Zhang (“Mr. Zhang”), founder, chairman and chief executive officer of iKang and certain of his affiliated entities, and FV Investment Holdings (“FountainVest”, together with Mr. Zhang and his affiliated entities, the “Buyer Group”) to acquire the Company in a “going private” transaction, the Board has formed a special committee of independent directors who are not affiliated to any member of the Buyer Group (the “Special Committee”) consisting of Ruby Lu, Daqing Qi and Gavin Zhengdong Ni to evaluate the Proposal.
On 15 September, La-Z-Boy Incorporated (NYSE:LZB) shares advanced 2.89% and was closed at $28.15. LZB EPS growth in last 5 year was 15.60%. La-Z-Boy Incorporated (NYSE:LZB) year to date (YTD) performance is 5.84%.
Headquartered in Monroe, Mich., La-Z-Boy has been producing some of the world’s most comfortable furniture for over 88 years. The company manufactures a full line of comfortable products for the living room and family room, including the company’s world-famous recliners, reclining sofas and love seats, sleep sofas, modular furniture and leather upholstery, as well as stationary sofas, love seats and chairs.
On 8 September, it was reported La-Z-Boy Incorporated (NYSE:LZB) celebrated mothers across the U.S. and Canada today by recognizing the ups – and downs – that go along with getting their children back-to-school. By creating a community of parents who can share their stories of the chaos, they can #TakeComfort in knowing they are not alone.
LivePerson Inc. (NASDAQ:LPSN) shares fell -0.97% in last trading session and ended the day at $8.17. LPSN Gross Margin is 73.10% and its has a return on assets of -5.50%. LivePerson Inc. (NASDAQ:LPSN) quarterly performance is -20.76%.
LivePerson, Inc. (NASDAQ: LPSN) offers a cloud-based platform that enables businesses to proactively connect in real time with their customers via chat, voice, and content delivery at the right time, through the right channel — including websites, social media, and mobile devices. This intelligent engagement is driven by real-time behavioral analytics, producing connections based on a true understanding of business objectives and customer needs.
LivePerson, Inc. (NASDAQ:LPSN), announced that Michael Montour has joined LivePerson as senior vice president of North American sales, under the leadership of Dustin Dean, executive vice president of Global Sales and Customer Success. He rejoins the company after more than two years as senior vice president of sales at Needle, a provider of advocate-assisted commerce.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) caters to the Healthcare space. Its weekly performance is -24.63%. On the last day of trading company shares ended up at $21.02. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) distance from 50-day simple moving average (SMA50) is -23.69%.
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery.
Canaccord Genuity started coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a research note issued to investors on Monday morning, The Fly reports. The firm issued a buy rating and a $35.00 target price on the stock.
Leave a Reply